Selected coverage of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, ...
Breyanzi, a CAR-T cell therapy, shows promise for relapsed or refractory CLL and SLL, achieving a 47% response rate and 18% complete remission rate. CAR-T therapy modifies patient T cells to target ...
Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback